Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: ASOS CEO to leave; warns on profit amid costs

Mon, 11th Oct 2021 07:50

(Alliance News) - Stocks in London are set to open lower on Monday, following a poor finish in New York on Friday and ahead of a key week for inflation readings.

In early UK company news, ASOS said Chief Executive Nick Beighton is stepping down, as it warned on profit in the year ahead due to cost pressures and the falling away of Covid-19-related benefits. AstraZeneca reported positive results for its Covid-19 antibody combination. Electric vehicle charging network Pod Point said it is mulling a London IPO.

IG says futures indicate the FTSE 100 index of large-caps to open down 25.95 points, or 0.4%, at 7,069.60 on Monday. The FTSE 100 closed up 17.51 points, or 0.2%, at 7,095.55 on Friday.

"Even though European markets closed lower on Friday, they still managed to finish the week higher, as did US markets, after what was a rather disappointing US jobs report, as we look forward to a week that sees US earnings season get underway in earnest, and where guidance is likely to be just as important as the headline numbers themselves," said Michael Hewson, chief market analyst at CMC Markets.

Data on Friday showed US nonfarm payrolls majorly disappointed in September. Total nonfarm payroll employment rose by 194,000 in September, less than half the 500,000 new jobs expected by analysts, according to FXStreet.

The Dow Jones Industrial Average ended flat, the S&P 500 down 0.2%, and the Nasdaq Composite down 0.5%.

The mood has lifted at the start of the new week in Asia as traders look ahead to some key inflation data this week.

The Nikkei 225 index in Tokyo ended up 1.6%. Against the yen, the dollar rose strongly to JPY112.74 versus JPY112.03.

In China, the Shanghai Composite was up 0.2%, while the Hang Seng index in Hong Kong rallied 1.9%. The S&P/ASX 200 in Sydney closed down 0.3%, however.

While Monday's economic calendar is quiet, later this week are inflation prints from the US and China.

Fuelling inflation jitters ahead of this, Brent oil was trading at USD83.68 a barrel early Monday, higher than USD83.15 late Friday.

"Fears that inflation will spike yet higher, and thus also become more entrenched than expected, are unlikely to ease this week," said Societe Generale.

In early UK company news, AstraZeneca said its long-acting antibody combination reduced severe Covid-19 or death in patients with mild-to-moderate symptoms.

The trial met its primary endpoint, with a dose of AZD7442 cutting the risk of developing severe Covid or death by 50% compared to placebo in outpatients who had been symptomatic for seven days or less.

A total of 90% of the participants enrolled for the Tackle phase three study were from populations at high risk of progression to severe Covid-19, including those with co-morbidities.

AstraZeneca said it will be discussing the data with health authorities, having last week announced the submission of a request to the US Food & Drug Administration for emergency use authorisation for AZD7442.

Online clothing retailer ASOS unveiled a board shake-up alongside its annual results, which showed a profit hike. However, the fast fashion firm warned on the year ahead amid supply chain issues and other cost pressures.

Revenue for the financial year to August 31 jumped 20% to GBP3.91 billion as retail sales grew 19% to GBP3.78 billion, while pretax profit rose 25% to GBP177.1 million.

However, sales growth in the year ahead is expected to be in the range of 10% to 15%, with interim revenue growth in "mid-single digits". This reflects tougher comparables and industry-wide supply chain pressures. The company expects sales to accelerate in the second half of the year and has laid out plans to generate GBP7 billion of annual revenue over the medium-term.

Adjusted pretax profit for the 2022 financial year is expected around GBP110 million to GBP140 million. This would be well below the GBP193.6 million registered for the financial year just ended.

ASOS flagged "notable cost headwinds", including inbound freight costs, Brexit duty annualisation, outbound delivery costs and labour cost inflation. It also said financial 2021 adjusted profit included GBP67.3 million in Covid-19-rated benefit.

"Looking ahead, while our performance in the next 12 months is likely to be constrained by demand volatility and global supply chain and cost pressures, we are confident in our ability to capture the sizeable opportunities ahead," said Chief Financial Officer & Chief Operating Officer Mat Dunn.

ASOS shook up its board to "underpin delivery of the next phase of its global growth strategy". CEO Beighton is stepping down after 12 years with ASOS, including six as CEO, and a search is underway for his replacement.

CFO Dunn has added the COO role and will run day-to-day operations, effective immediately. Katy Mecklenburgh, currently director of group finance, has become interim CFO.

Chair Adam Crozier, whose decision to step down was previously announced, will be succeeded by Senior Independent Non-Executive Director Ian Dyson.

"Over the last three years we have made significant progress...At the same time, however, we recognise that there is more to do to accelerate the pace and intensity of commercial execution," said Crozier.

EDF-backed electric vehicle charging firm Pod Point is mulling a float on the London Stock Exchange.

Pod Point, founded in 2009, said it is "one of the original" electric vehicle charging providers in the UK. It expects around 25 million charge points will be needed in the UK by 2040, and its outlook is underpinned by a favourable regulatory and political backdrop.

The initial public offer would comprise a primary offer of new shares with proceeds to support Pod Point's growth plans, and an offer of existing shares to be sold by Legal & General Capital Investments. Majority shareholder EDF is expected to retain a stake above 50% after the business floats.

"Today marks an exciting milestone for the business. I am looking forward to helping steer Pod Point's superb team to take advantage of the significant growth opportunity ahead of us. I have no doubt that the company will continue to thrive as one of the United Kingdom's leading EV charging companies, delivering further value to all its stakeholders and ensuring that travel does not damage the earth," said Chair Gareth Davis.

Davis is chair at M&C Saatchi, and has previously held the same role at other London listings, such as William Hill, Ferguson and DS Smith. He was CEO at Imperial Brands until 2010.

Sterling was quoted at USD1.3669 early Monday, up against USD1.3645 at the London equities close on Friday. The euro traded at USD1.1584, firm versus USD1.1578 late Friday.

Britain is on a fresh collision course with the EU over the UK Brexit minister's demand to drop the role of the European Court of Justice from the Northern Ireland Protocol.

David Frost was accused of using an unassailable "red line" to create a "destabilising stand-off" with Brussels amid indications the government was edging closer to overriding parts of its own post-Brexit agreement.

The Tory peer will use a speech in Portugal on Tuesday to say the EU must go further than scrapping its prohibition on British sausages crossing the Irish Sea.

Gold was quoted at USD1,755.97 an ounce early Monday, lower than USD1,759.55 on Friday.

The US third-quarter earnings season starts on Wednesday with financial firms BlackRock and JP Morgan Chase. Bank of America, Morgan Stanley and Citigroup follow on Thursday.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.